دورية أكاديمية

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

التفاصيل البيبلوغرافية
العنوان: Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial
المؤلفون: Romera, Alvaro, Peredpaya, Sergiy, Shparyk, Yaroslav, Bondarenko, Igor, Mendonça Bariani, Giovanni, Abdalla, Kathia Cristina, Roca, Enrique, Franke, Fábio, Melo Cruz, Felipe, Ramesh, Anita, Ostwal, Vikas, Shah, Pradeep, Rahuman, Sajeed Abdul, Paravisini, Alexandra, Huerga, Camino, Del Campo García, Ana, Millán, Susana
المصدر: In The Lancet Gastroenterology & Hepatology December 2018 3(12):845-855
قاعدة البيانات: ScienceDirect
الوصف
تدمد:24681253
DOI:10.1016/S2468-1253(18)30269-3